Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Smith-and-Nephew stock | $42.17

Own Smith-and-Nephew stock in just a few minutes.

Fact checked

Smith & Nephew plc is a medical devices business based in the US. Smith-and-Nephew shares (SNN) are listed on the NYSE and all prices are listed in US Dollars. Smith-and-Nephew employs 17,500 staff and has a trailing 12-month revenue of around USD$4.7 billion.

How to buy shares in Smith-and-Nephew

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Smith-and-Nephew. Find the stock by name or ticker symbol: SNN. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Smith-and-Nephew reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$42.17, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Smith-and-Nephew, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Smith-and-Nephew. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Smith-and-Nephew share price

Use our graph to track the performance of SNN stocks over time.

Smith-and-Nephew shares at a glance

Information last updated 2020-12-29.
Latest market closeUSD$42.17
52-week rangeUSD$25.5242 - USD$49.6238
50-day moving average USD$40.4779
200-day moving average USD$39.8449
Wall St. target priceUSD$48.17
PE ratio 47.5336
Dividend yield USD$0.58 (1.36%)
Earnings per share (TTM) USD$0.892

Buy Smith-and-Nephew shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Sofi Invest
Stocks, ETFs, Cryptocurrency
A free way to invest in stocks, ETFs and crypto.
Interactive Brokers
Stocks, Forex
$0 + $0.65/contract, $1 minimum
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Stocks, ETFs
Stocks, Options, ETFs, Cryptocurrency
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
$0 for US stocks
Stocks, Options, ETFs
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Smith-and-Nephew stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Smith-and-Nephew price performance over time

Historical closes compared with the close of $42.17 from 2020-12-31

1 week (2021-01-13) N/A
1 month (2020-12-24) 0.26%
3 months (2020-10-20) N/A
6 months (2020-07-20) N/A
1 year (2020-01-20) N/A
2 years (2019-01-20) N/A
3 years (2018-01-20) N/A
5 years (2016-01-20) N/A

Is Smith-and-Nephew under- or over-valued?

Valuing Smith-and-Nephew stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Smith-and-Nephew's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Smith-and-Nephew's P/E ratio

Smith-and-Nephew's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 48x. In other words, Smith-and-Nephew shares trade at around 48x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

Smith-and-Nephew's PEG ratio

Smith-and-Nephew's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 2.5602. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Smith-and-Nephew's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Smith-and-Nephew's EBITDA

Smith-and-Nephew's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$957 million.

The EBITDA is a measure of a Smith-and-Nephew's overall financial performance and is widely used to measure a its profitability.

Smith-and-Nephew financials

Revenue TTM USD$4.7 billion
Operating margin TTM 11.33%
Gross profit TTM USD$3.8 billion
Return on assets TTM 3.59%
Return on equity TTM 7.89%
Profit margin 8.34%
Book value $11.408
Market capitalisation USD$17.5 billion

TTM: trailing 12 months

Shorting Smith-and-Nephew shares

There are currently 463,620 Smith-and-Nephew shares held short by investors – that's known as Smith-and-Nephew's "short interest". This figure is 56.1% up from 297,000 last month.

There are a few different ways that this level of interest in shorting Smith-and-Nephew shares can be evaluated.

Smith-and-Nephew's "short interest ratio" (SIR)

Smith-and-Nephew's "short interest ratio" (SIR) is the quantity of Smith-and-Nephew shares currently shorted divided by the average quantity of Smith-and-Nephew shares traded daily (recently around 345985.07462687). Smith-and-Nephew's SIR currently stands at 1.34. In other words for every 100,000 Smith-and-Nephew shares traded daily on the market, roughly 1340 shares are currently held short.

However Smith-and-Nephew's short interest can also be evaluated against the total number of Smith-and-Nephew shares, or, against the total number of tradable Smith-and-Nephew shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Smith-and-Nephew's short interest could be expressed as 0% of the outstanding shares (for every 100,000 Smith-and-Nephew shares in existence, roughly 0 shares are currently held short) or 0% of the tradable shares (for every 100,000 tradable Smith-and-Nephew shares, roughly 0 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Smith-and-Nephew.

Find out more about how you can short Smith-and-Nephew stock.

Smith-and-Nephew share dividends

Dividend payout ratio: 657.89% of net profits

Recently Smith-and-Nephew has paid out, on average, around 657.89% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 1.36% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Smith-and-Nephew shareholders could enjoy a 1.36% return on their shares, in the form of dividend payments. In Smith-and-Nephew's case, that would currently equate to about $0.58 per share.

Smith-and-Nephew's payout ratio would broadly be considered high, and as such this stock could appeal to those looking to generate an income. Bear in mind however that companies should normally also look to re-invest a decent amount of net profits to ensure future growth.

Smith-and-Nephew's most recent dividend payout was on 28 October 2020. The latest dividend was paid out to all shareholders who bought their shares by 1 October 2020 (the "ex-dividend date").

Have Smith-and-Nephew's shares ever split?

Smith-and-Nephew's shares were split on a 2499:1000 basis on 15 October 2014. So if you had owned 1000 shares the day before before the split, the next day you'd have owned 2499 shares. This wouldn't directly have changed the overall worth of your Smith-and-Nephew shares – just the quantity. However, indirectly, the new 60% lower share price could have impacted the market appetite for Smith-and-Nephew shares which in turn could have impacted Smith-and-Nephew's share price.

Smith-and-Nephew share price volatility

Over the last 12 months, Smith-and-Nephew's shares have ranged in value from as little as $25.5242 up to $49.6238. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Smith-and-Nephew's is 0.3721. This would suggest that Smith-and-Nephew's shares are less volatile than average (for this exchange).

Smith-and-Nephew overview

Smith & Nephew plc develops, manufactures, and sells medical devices worldwide. The company offers knee implant products for specialized knee replacement procedures; hip implants for the reconstruction of hip joints; and trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures. It also provides sports medicine joint repair products for surgeons, including an array of instruments, technologies, and implants necessary to perform minimally invasive surgery of the joints, such as the repair of soft tissue injuries and degenerative conditions of the knee, hip, and shoulder, as well as meniscal repair systems. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, high definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, including biologics and other bioactive technologies for debridement and dermal repair/regeneration, as well as regenerative medicine products including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. It primarily serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site